Unknown

Dataset Information

0

Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.


ABSTRACT: Graft-versus-host disease (GVHD) is a leading cause of nonrelapse mortality after allogeneic hematopoietic cell transplantation. T cell costimulation by CD28 contributes to GVHD, but prevention is incomplete when targeting CD28, downstream mammalian target of rapamycin (mTOR), or Aurora A. Likewise, interleukin-6 (IL-6)-mediated Janus kinase 2 (JAK2) signaling promotes alloreactivity, yet JAK2 inhibition does not eliminate GVHD. We provide evidence that blocking Aurora A and JAK2 in human T cells is synergistic in vitro, prevents xenogeneic GVHD, and maintains antitumor responses by cytotoxic T lymphocytes (CTLs). Aurora A/JAK2 inhibition is immunosuppressive but permits the differentiation of inducible regulatory T cells (iTregs) that are hyperfunctional and CD39 bright and efficiently scavenge adenosine triphosphate (ATP). Increased iTreg potency is primarily a function of Aurora A blockade, whereas JAK2 inhibition suppresses T helper 17 (TH17) differentiation. Inhibiting either Aurora A or JAK2 significantly suppresses TH1 T cells. However, CTL generated in vivo retains tumor-specific killing despite Aurora A/JAK2 blockade. Thus, inhibiting CD28 and IL-6 signal transduction pathways in donor T cells can increase the Treg/Tconv ratio, prevent GVHD, and preserve antitumor CTL.

SUBMITTER: Betts BC 

PROVIDER: S-EPMC6368389 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.

Betts Brian C BC   Veerapathran Anandharaman A   Pidala Joseph J   Yang Hua H   Horna Pedro P   Walton Kelly K   Cubitt Christopher L CL   Gunawan Steven S   Lawrence Harshani R HR   Lawrence Nicholas J NJ   Sebti Said M SM   Anasetti Claudio C  

Science translational medicine 20170101 372


Graft-versus-host disease (GVHD) is a leading cause of nonrelapse mortality after allogeneic hematopoietic cell transplantation. T cell costimulation by CD28 contributes to GVHD, but prevention is incomplete when targeting CD28, downstream mammalian target of rapamycin (mTOR), or Aurora A. Likewise, interleukin-6 (IL-6)-mediated Janus kinase 2 (JAK2) signaling promotes alloreactivity, yet JAK2 inhibition does not eliminate GVHD. We provide evidence that blocking Aurora A and JAK2 in human T cell  ...[more]

Similar Datasets

| S-EPMC4313840 | biostudies-other
| S-EPMC4588578 | biostudies-literature
| S-EPMC4102782 | biostudies-literature
| S-EPMC5816153 | biostudies-literature
| S-EPMC4876606 | biostudies-literature
| S-EPMC6337874 | biostudies-literature
2015-11-29 | GSE73810 | GEO
| S-EPMC10145933 | biostudies-literature
| S-EPMC4089459 | biostudies-literature
| S-EPMC4459945 | biostudies-literature